CADTH Canadian Drug Expert Committee recommendation: Migalastat (Galafold -- Amicus therapeutics) indication : Fabry disease
The CADTH Canadian Drug Expert Committee (CDEC) recommends that migalastat be reimbursed for the long-term treatment of adults with a confirmed diagnosis of Fabry Disease (FD) (alpha-galactosidase [alpha- Gal A]) and who have an alpha-Gal A mutation determined to be amenable by an in vitro assay
| Corporate Authors: | , |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, January 2018
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that migalastat be reimbursed for the long-term treatment of adults with a confirmed diagnosis of Fabry Disease (FD) (alpha-galactosidase [alpha- Gal A]) and who have an alpha-Gal A mutation determined to be amenable by an in vitro assay |
|---|---|
| Item Description: | "Final." |
| Physical Description: | 1 PDF file (8 pages) |